
Andrew D. Leavitt MD
Blood Banking & Transfusion Medicine, Clotting Disorder, Hemophilia & Bleeding Disorder
Professor, Laboratory Medicine, UCSF School of Medicine
Join to View Full Profile
505 Parnassus AveSan Francisco, CA 94143
Phone+1 415-514-3432
Fax+1 415-514-3433
Dr. Leavitt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1988 - 1989
University of MichiganResidency, Internal Medicine, 1986 - 1988
University of MichiganInternship, Internal Medicine, 1984 - 1985
Harvard Medical SchoolClass of 1984
Certifications & Licensure
CA State Medical License 1989 - 2027
MI State Medical License 1987 - 1991
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Publications & Presentations
PubMed
- Duffy-null variant and practical implications for patient care: a scoping review.Edgar Asiimwe, Thye Peng Ngo, Elad Ziv, Andrew D Leavitt
BMJ Open. 2025-11-19 - 3 citationsCorticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance.Barbara A Konkle, Flora Peyvandi, Graham R Foster, Cedric Hermans, Vincenzo La Mura
Journal of Thrombosis and Haemostasis. 2025-07-01 - Decoding functional hematopoietic progenitor cells in the adult human lung.Catharina Conrad, Mélia Magnen, Jessica Tsui, Harrison Wismer, Mohammad Naser
Blood. 2025-05-01
Abstracts/Posters
- Von Willebrand Disease Minimize Menorrhagia (VWDMin) TrialAndrew D. Leavitt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patien...Andrew D. Leavitt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative NeoplasmsAndrew D. Leavitt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Pfizer’s Gene Therapy for Rare Genetic Bleeding Disorder Succeeds in Late-Stage TrialJuly 24th, 2024
UCSF Treats Man Who Developed Rare Blood Clot After Johnson and Johnson VaccineApril 30th, 2021
Bay Area Patient Is First MAN to Get Blood Clot After J&J VaccinationApril 26th, 2021
Grant Support
- Molecular Mechanisms Of TPO Induced MPL Signaling In MegakaryocytesNational Heart, Lung, And Blood Institute2001–2005
- Novel Systems For The Study Of MegakaryocytopoiesisNational Heart, Lung, And Blood Institute1996–2000
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









